Guerbet Drug Patent Portfolio
Guerbet owns 1 orange book drug protected by 3 US patents Given below is the list of Guerbet's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11590246 | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process | 17 Jan, 2040 | Active |
| US10973934 | Gadolinium bearing PCTA-based contrast agents | 06 Aug, 2039 | Active |
| US8114863 | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging | 19 Sep, 2028 | Active |
Latest Legal Activities on Guerbet's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Guerbet.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 29 Feb, 2024 | US8114863 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US8114863 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Aug, 2023 | US8114863 |
|
Email Notification
Critical
| 28 Feb, 2023 | US11590246 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Feb, 2023 | US11590246 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Feb, 2023 | US11590246 |
|
Issue Notification Mailed
Critical
| 08 Feb, 2023 | US11590246 |
| Initial letter Re: PTE Application to regulating agency | 03 Feb, 2023 | US8114863 |
| Dispatch to FDC | 01 Feb, 2023 | US11590246 |
|
Application Is Considered Ready for Issue
Critical
| 01 Feb, 2023 | US11590246 |
|
Issue Fee Payment Received
Critical
| 16 Jan, 2023 | US11590246 |
|
Issue Fee Payment Verified
Critical
| 16 Jan, 2023 | US11590246 |
|
Mail Notice of Allowance
Critical
| 14 Oct, 2022 | US11590246 |
|
Electronic Review
Critical
| 14 Oct, 2022 | US11590246 |
|
Email Notification
Critical
| 14 Oct, 2022 | US11590246 |
Guerbet Drug Patents' Oppositions Filed in EPO
Guerbet drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 02, 2021, by Cohausz & Florack Patent- Und Rechtsanwälte Partnerschaftsgesellschaft Mbb. This opposition was filed on patent number EP19753296A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19753296A | Aug, 2021 | COHAUSZ & FLORACK Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
Guerbet's Family Patents
Guerbet Drug List
Given below is the complete list of Guerbet's drugs and the patents protecting them.
1. Elucirem
Elucirem is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11590246 | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
17 Jan, 2040
(15 years from now)
| Active |
| US10973934 | Gadolinium bearing PCTA-based contrast agents |
06 Aug, 2039
(14 years from now)
| Active |
| US8114863 | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
19 Sep, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elucirem's drug page